|The Drug Discovery Process: From Inception to Prescription||Return to listing|
Charles River Presents: From Inception to Prescription- An Overview of Drug Discovery and Preclinical Development
Drug discovery can be a long and arduous process starting with validation of target identification through selection of lead candidate and on to preclinical demonstration of safety and efficacy. In this complimentary seminar, we will present a case study review of these steps in drug discovery as well as key considerations in preclinical development that are necessary for therapeutic approval and registration.
Make sure you sign up soon, as only 60 spaces are available for this event!
Dr. Joseph A. Cornicelli- Scientific Advisor, Inflammation and Cardiovascular Pharmacology Services
Joe Cornicelli, Ph.D. is the Director of Inflammation and Cardiovascular Pharmacology Services for Charles River Laboratories, and has over 22 years of experience in drug discovery and development. Trained at the University of Cincinnati, Dr. Cornicelli completed post-doctoral fellowships at the Mayo Clinic Foundation and Columbia University, where he was part of the research faculty in the Department of Medicine. He joined Warner-Lambert in 1985 where he served as a Research Fellow in the inflammation and cardiovascular therapeutic areas. In 2007, Dr. Cornicelli joined Charles River as the Director of Inflammation and Cardiovascular Pharmacology Services. He is responsible for directing discovery efforts for the assessment of potential therapeutics for inflammatory, metabolic and cardiovascular disorders. Dr. Cornicelli is a Fellow of the American Heart Association.
Dr. Joseph Francisco- Senior Client Services Scientist, Business Development
Joe Francisco is a Senior Scientist in the business development unit at Charles River. In this role he provides scientific and regulatory guidance on the preclinical development of small molecule drugs and biotechnology derived therapeutics. His primary area of focus is the pharmacology and toxicology of therapeutic proteins, with an emphasis on monoclonal antibodies. Previously within Charles River Joe was a Senior Program Advisor in the Navigator group. In these roles he has provided strategic and tactical guidance to a diverse array of domestic and international pharmaceutical and biotechnology companies ranging from small virtual companies to large multinational organizations. Joe also has experience as an independent consultant, working with small biotechnology companies to establish preclinical strategies to support the development of novel therapeutics. Prior to joining Charles River, Joe had spent seven years at Seattle Genetics in positions of increasing responsibility focusing on the research and development of therapeutic monoclonal antibodies and antibody-drug conjugates. Before joining Seattle Genetics Joe had been a scientist in the Protein Sciences division of Monsanto and a scientist in the Pharmaceutical Research Institute of Bristol-Myers Squibb. Joe received his PhD in Chemical Engineering from the University of Texas at Austin and his bachelor’s degree in Chemical Engineering and Biochemistry from Rice University. He has co-authored over 20 scientific publications and a number of US and international patent applications.
Melody A. McDonough- Director of Business Development, Charles River Discovery Services
Melody is responsible for seeking out, managing and developing all opportunity within academia, foundation and government nationwide. In addition, Melody is responsible for those same activities but within the biotech and pharmaceutical industry on the eastern coast of the United States. She has been involved in assisting academia and small biotech secure more than $5M during 2013. Melody received a Masters in Government Contracting from Villanova and Bachelors in Business from Excelsior.
|Date:||Wednesday, August 20, 2014|
|Time:||11:00 AM - 1:30 PM|
|Sponsor:||NC TraCS (Translational and Clinical Sciences) Institute: NIH CTSA at UNC-CH|
|For more information, contact the event administrator: Andrew Kant email@example.com|
THIS EVENT HAS EXPIRED